Document:

EXHIBIT 10.3

                      SPORTAN UNITED INDUSTRIES CORPORATION
                            SCIENTIFIC ADVISORY BOARD
                                MEMBER AGREEMENT

      This Sportan United Industries  Scientific Advisory Board Member Agreement
(this  "Agreement")  is made and entered  into as of the 9th day of July,  2004,
(the "Effective  Date"),  by and between Yong Zhao  (hereinafter  referred to as
"Advisory  Member") and Sportan United Industries  (Sportan)  (together with any
successor to the business of Sportan United Industries by merger,  consolidation
or other form of business  combination  hereinafter  referred to collectively as
"Sportan United Industries").

                              W I T N E S S E T H:

      WHEREAS,  Sportan United  Industries  wishes to retain  Advisory Member to
serve on the  PharmaFrontiers  Scientific Advisory Board (the "Advisory Board"),
and Advisory Member has agreed to serve on the terms and conditions below; and

      WHEREAS,  Sportan'  success  requires the  protection of its  intellectual
property, proprietary information and goodwill;

      NOW, THEREFORE,  the parties hereto,  intending to be legally bound, agree
as follows:

1.    Retention as Advisory Board Member

      Sportan agrees to retain Advisory Member as a member of its Advisory Board
for a term of three (3) years from the Effective  Date.  Advisory  Member agrees
that Advisory Member will devote the amount of time,  skill,  and efforts during
the term of this  Agreement  to the  affairs  of  Sportan  as may be  reasonably
requested and required of Advisory Member.

2.    Compensation

      2.1 Advisor Fee. As  compensation  for serving as a member of the Advisory
Board of  Sportan,  Sportan  agrees  upon the  execution  and  delivery  of this
Agreement  to  Sportan,  to pay to Advisory  Member  $5,000  ("Signing  Bonus)".
Additionally, commencing one month from the date of the signing hereof, Advisory
Member  shall  receive  a  monthly  payment  of  $2,000  durig  the term of this
Agreement  ("Monthly  Payment").  Upon the  Technology  Transfer  (as defined in
Section 2.2 below),  this  Monthly  Payment  will be increased to $3,000 and the
Advisory Member shall receive $25,000 bonus payment.

      2.2 Incentive  Bonus. In addition to the payment  described in Section 2.1
above,  Advisory  Member shall receive an option based on the  reproduction,  by
Sportan or agents thereof, of (i) the experimental  results described in Zhao et
al.  (2003) PNAS  100(5):2426-31;  and (ii) the  subject  matter  described  and
claimed  in U.S.  Patent  Application  No.  10/704,100  and its PCT  counterpart
PCT/US03/35539  ("Technology  Transfer").  Upon the  successful  completion of a
Technology  Transfer,  Advisory  Member shall be issued a  three-year  option to
purchase from Sportan up to 100,000  shares of common stock at a purchase  price
equal to the offering price of the private  equity  financing (as defined in the
Financing  & Strategic  Advisory  Agreement  by and between  Sportan and Sanders
Morris Harris dated June 12, 2004).

<PAGE>

      2.3  Reimbursement.  Advisory  Member shall be reimbursed up to $1,000 per
annum for all reasonable  out-of-pocket business expenses incurred in connection
with the performance of his or her duties under this Agreement.

      2.4 No Other Compensation. Advisory Member agrees and covenants that he or
she  will  not be owed any  compensation  other  than  what is  provided  for in
Sections 2.1, 2.2 and 2.3.

3.    Confidential and Proprietary Information; Documents

      3.1  Sportan  United   Industries   shall  provide  Advisory  Member  with
information   deemed  secret  and  confidential  by  Sportan.   Such  secret  or
confidential  information or know-how of Sportan  (referred to  collectively  as
"Confidential  Information") shall include,  without limitation,  the following:
the status and plans for research and development;  materials,  cells,  tissues,
and other biological samples and specimens; cell banking methods, apparatus, and
services; pending and planned patent applications (until published by the Patent
Office);  invention  disclosures;  research and technical data and  information;
methods  of  creating,  preparing,  and using  stem  cells and other  biological
materials;  license,  sublicense,  and other agreements relating to intellectual
property rights;  Sportan' plans;  customer or contact information;  contributor
information;  strategies,  costs,  prices,  uses,  applications  of products and
services; results of and data from investigations or experiments; all apparatus,
products, processes, compositions, samples, formulas, computer programs, pricing
policy,  financial  information,  and methods of doing  business;  policy and/or
procedure manuals,  training and recruiting  procedures;  accounting procedures;
the status and content of Sportan' contracts with its contributors, clients, and
customers;  Sportan' business philosophy,  and servicing methods and techniques;
all at any time used,  developed,  or investigated by Sportan,  before or during
the term of this Agreement,  which are not generally  available to the public or
which are maintained as confidential by Sportan.

      3.2 Advisory Member  recognizes and acknowledges that Advisory Member will
have  access  to  certain  information  of  Sportan  that  is  confidential  and
proprietary  and constitutes  valuable and unique property of Sportan.  Advisory
Member agrees that Advisory  Member will not (except as reasonably  necessary to
perform  Advisory  Member's  duties  hereunder)  at any time,  either  during or
subsequent  to the term of this  Agreement,  disclose  to others,  use,  copy or
permit to be copied,  except in pursuance of Advisory  Member's duties on behalf
of Sportan, its successors,  assigns or nominees, or as required by the order of
any tribunal having  jurisdiction or by mandatory  provisions of applicable law,
any  Confidential  Information or know-how of Sportan  without the prior written
consent of the President of Sportan.  Advisory Member further agrees to maintain
in confidence the Confidential  Information and any confidential  information of
third  parties  received  as a result of  Advisory  Member's  relationship  with
Sportan.

      3.3 Advisory  Member further  agrees to deliver to Sportan  promptly after
the  termination  or  expiration of this  Agreement,  all  biological  materials
correspondence,  memoranda, notes, records, drawings, sketches, plans, customer,
client and/or contributor lists,  product  compositions,  or other documents and
all copies thereof (all of which are hereafter  referred to as the "Documents"),
made,  authored,  composed,  conceived,  reduced to  practice,  or  received  by

                                       2
<PAGE>

Advisory  Member,  solely or  jointly  with  others,  and which are in  Advisory
Member's  possession,  custody, or control at such date and which are related in
any manner to the past,  present,  or anticipated  business of Sportan and which
contain, or are based on derived from, any Confidential Information of Sportan.

      3.4 Advisory  Member further agrees that Advisory  Member will not, during
the term of this Agreement,  and on behalf of Sportan accept or agree to receive
from persons not employed by Sportan, any confidential information not belonging
to Sportan,  unless prior to such receipt or  acceptance a valid  agreement  has
been executed  between Sportan and the disclosing party that states that Sportan
will not be in a confidential  relationship with the disclosing party.  Advisory
Member  further  agrees that  Advisory  Member will not use in  violation of any
confidentiality   obligation  binding  upon  Advisory  Member  any  confidential
information  belonging to Advisory Member's employer or any former employer,  or
any other third parties.

      3.5  Advisory  Member  agrees  that,  during  the term of this  Agreement,
Advisory  Member  will  not  directly  or  indirectly,  either  as an  employee,
employer,  consultant,  agent, principal,  partner,  corporate officer, Advisory
Member,  or in any  other  individual  or  representative  capacity,  engage  or
participate  in any  "Competitive  Business"  anywhere  in the United  States of
America,  Canada or the European Union. As used herein, a "Competitive Business"
is defined  as any  business,  including  those  relating  to stem cells or cell
banking, which provides the same or substantially the same products, services or
licenses to intellectual  property rights,  in whole or in part, as are provided
by Sportan during the term of this Agreement.

      3.6 In the event of a breach or threatened breach of any of the provisions
of Section 3, Sportan shall be entitled to an injunction  ordering the return of
such Documents and any and all copies thereof and  restraining  Advisory  Member
from using or  disclosing,  for  Advisory  Member's  benefit  or the  benefit of
others,  in whole or in part, any  Confidential  Information,  including but not
limited  to  the  Confidential   Information   which  such  Documents   contain,
constitute,  or  embody.  Advisory  Member  further  agrees  that any  breach or
threatened  breach of any of the provisions of Section 3 would cause irreparable
injury to Sportan  for which it would have no  adequate  remedy at law.  Nothing
herein  shall be  construed  as  prohibiting  Sportan  from  pursuing  any other
remedies available to it for any such breach or threatened breach, including the
recovery of damages.

4.    Inventions and Other Intellectual Property

      4.1 Advisory  Member  agrees to hold in complete  trust for the benefit of
Sportan,  and to disclose  promptly and fully to Sportan in writing,  and hereby
assigns, and binds Advisory Member's heirs, executors,  administrators,  and all
legal representatives to assign, to Sportan any and all inventions, discoveries,
ideas, concepts,  improvements,  copyrightable works, biological materials,  and
other  developments  (all  of the  above  are  collectively  referred  to as the
"Developments")  conceived,  reduced to practice,  authored, made, discovered or
developed  by him,  solely  or  jointly  with  others,  during  the term of this
Agreement,  whether  during or outside  of usual  working  hours and  whether on
Sportan'  premises or not, which result from Advisory  Member's work for Sportan
under this  Agreement,  and/or are based on, or derived or result  from,  any of
PharmaFrontier's  Confidential Information.  Any and all such Developments shall
be  the  sole  and   exclusive   property   of  Sportan,   whether   patentable,
copyrightable,  or neither, and Advisory Member agrees that Advisory Member will
assist and fully  cooperate  in every way, at  Sportan'  expense,  in  securing,
maintaining, and enforcing, for the benefit of Sportan or its designee, patents,
copyrights or other types of proprietary or intellectual property protection for
such  Developments in any and all countries.  Advisory Member  acknowledges  and

                                       3
<PAGE>

agrees that any and all such Developments conceived, created, or authored by him
is a "work  made for  hire," as  defined  by the  federal  copyright  laws,  and
therefore all  copyrights in and to such works are and will be owned by Sportan.
To the extent that Advisory Member authors any copyrightable  work in any medium
during  the term of this  Agreement  which  relates  or  pertains  in any way to
Sportan or any of its operations or activities and which is held not a work made
for hire,  Advisory  Member  hereby  assigns  all right,  title,  and  interest,
including  but not limited to all rights of  copyright,  in and to such works to
Sportan.

      4.2 Without limiting the foregoing,  Advisory Member agrees at the request
of Sportan (but without  additional  compensation  from Sportan during  Advisory
Member's  employment  by  Sportan) to execute any and all papers and perform all
lawful  acts  which  Sportan  deems  necessary  for  the  preparation,   filing,
prosecution,  and  maintenance  of  applications  for United  States and foreign
letters  patent,   or  for  United  States  and  foreign   copyrights,   on  the
Developments,  and to execute such instruments as are necessary or convenient to
assign to Sportan,  its  successors,  assigns or  nominees,  all of the Advisory
Member's right,  title,  and interest in the Developments and the like, so as to
establish, maintain or perfect, in Sportan, its successors, assigns or nominees,
the entire right,  title, and interest to the Developments,  and also to execute
any instruments necessary or which Sportan may deem desirable it connection with
any  continuation,  renewal  or  reissue  thereof,  or in  the  conduct  of  any
proceedings or litigation in regard thereto.

      4.3  All  expenses  incurred  by the  Advisory  Member  by  reason  of the
performance  of any of the  obligations  set forth in this Section on Inventions
shall be borne by Sportan.  Should the Advisory Member's assistance be requested
by Sportan after  termination  of this  Agreement,  Sportan will  compensate the
Advisory Member at a reasonable rate.

5.    Miscellaneous

      5.1 This  Agreement is made and entered into as of the Effective  Date and
the rights and obligations of the parties hereto shall be binding upon the heirs
and legal  representatives of the Advisory Member and the successors and assigns
of Sportan.  This Agreement may be assigned by Sportan (including  assignment by
operation  of  law to any  successor  to the  business  of  Sportan  by  merger,
consolidation  or other  business  combination)  without the consent of Advisory
Member  but is  personal  to the  Advisory  Member and no  rights,  duties,  and
obligations of Advisory Member  hereunder may be assigned without the consent of
Sportan or its assigns, which may be granted or withheld in its sole discretion.

      5.2 Sportan may terminate this Agreement at any time upon thirty (30) days
prior written notice to Advisory Member. No waiver or non-action with respect to
any breach by the other party of any provision of this Agreement, nor the waiver
or non-action with respect to any breach of the provisions of similar agreements
with other Advisory  Members shall be construed to be a waiver of any succeeding
breach of such provision, or as a waiver of the provision itself.

      5.3  Should  any  portions  hereof  be held to be  invalid  or  wholly  or
partially unenforceable, such holding shall not invalidate or void the remainder
of this  Agreement.  The portions held to be invalid or  unenforceable  shall be

                                       4
<PAGE>

revised and reduced in scope so as to be valid and  enforceable,  or, if such is
not possible,  then such portions  shall be deemed to have been wholly  excluded
with the same force and effect as if it had never been included herein.

      5.4 Advisory Member's obligations under Sections 3 and 4 of this Agreement
to Sportan  shall  survive the  termination  or  expiration  of this  Agreement.
Advisory Member and Sportan agree that, because damages at law for any breach or
nonperformance of this Agreement by Advisory Member, while recoverable,  are and
will be  inadequate,  this  Agreement  may be  enforced  in equity  by  specific
performance, injunction, accounting or otherwise.

      5.5 This Agreement  supersedes,  replaces and merges any and all prior and
contemporaneous  understandings,  representations,  agreements  and  discussions
relating to the same or similar subject matter as that of this Agreement between
Advisory  Member and  Sportan  and  constitutes  the sole and  entire  agreement
between the Advisory  Member and Sportan  with respect to the subject  matter of
this Agreement.

      5.6 The laws of the State of Texas, excluding any conflicts of law rule or
principle  that  might  otherwise  refer  to  the  substantive  law  of  another
jurisdiction,  will  govern  the  interpretation,  validity  and  effect of this
Agreement  without regard to the place of execution or the place for performance
thereof, and Sportan and Advisory Member agree that the state and federal courts
in Harris County, Texas, shall have personal jurisdiction and venue over Sportan
and Advisory  Member to hear all disputes  arising  under this  Agreement.  This
Agreement is to be at least partially performed in Harris County, Texas.

      5.7 All notices and other  communications  required or permitted hereunder
or necessary or convenient in connection  herewith shall be in writing and shall
be deemed to have been given when mailed by registered  mail or certified  mail,
return receipt requested, as follows:

      If to Sportan United Industries, to:

      Mr. George R. Jarkesy, Jr.
      Sportan United Industries Corporation
      10211 Silver Leaf Lane
      Tomball, Texas 77375

      If to Advisory Member, to:

or to such other  addresses as either party may designate by notice to the other
party hereto in the manner specified in this section.

      5.8 This Agreement may not be changed or terminated orally, and no change,
termination  or  waiver of this  Agreement  or of any of the  provisions  herein
contained  shall be binding  unless made in writing and signed by both  parties,

                                       5
<PAGE>

and in the case of  Sportan  United  Industries,  by an  authorized  officer  of
Sportan United Industries. Any change or changes, from time to time, in Advisory
Member's  compensation shall not be, nor be deemed to be, a change,  termination
or waiver of this Agreement or of any of the provisions herein contained.

SPORTAN UNITED INDUSTRIES CORPORATION               ADVISORY MEMBER

By: /s/ Warren Lau                                  By: /s/ Yong Zhao
    -----------------------------                       --------------------
    Warren Lau, President                               Yong Zhao

                                       6EXHIBIT 10.4

                              EMPLOYMENT AGREEMENT

      This Employment  Agreement (this  "Agreement") is made and effective as of
the 23rd day of August,  2004, (the "Effective  Date"),  by and between David B.
McWilliams  (hereinafter  referred to as "Employee") and  PharmaFrontiers  Corp.
(hereinafter referred to as "PharmaFrontiers").

                              W I T N E S S E T H:

      WHEREAS, Employee desires employment with PharmaFrontiers on the terms and
conditions below; and

      WHEREAS,   PharmaFrontiers'   success   requires  the  protection  of  its
intellectual property,  proprietary information and goodwill and PharmaFrontiers
is willing to employ Employee, subject to the terms and conditions below; and

      NOW,   THEREFORE,   for  and  in   consideration   of  the  employment  by
PharmaFrontiers,  the compensation and other remuneration paid and to be paid by
PharmaFrontiers and received by the Employee for such employment,  and for other
good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged  by  Employee,  it is agreed by and between  the parties  hereto as
follows:

1.    Employment

      PharmaFrontiers  agrees to employ the Employee,  and Employee  agrees that
Employee will devote  Employee's full productive  time,  skill, and best efforts
during  Employee's  employment to such duties as may be  reasonably  assigned to
Employee.  Employee will faithfully and diligently  endeavor to further the best
interests  of  PharmaFrontiers  during  Employee's  employment.  PharmaFrontiers
acknowledges and authorizes  Employee to spend a nominal amount of time each day
for  work  outside  PharmaFrontiers.  Either  PharmaFrontiers  or  Employee  may
terminate this Agreement at any time for any or no reason.

2.    Duties and Title

      Employee  shall  have the title of and  shall  act as the Chief  Executive
Officer of PharmaFrontiers.  Employee shall have the following  responsibilities
and duties: Employee shall report to PharmaFrontiers' Board of Directors,  shall
have general  supervisions over the operations of the Company and will have such
other  duties  and  responsibilities  consistent  with  his  position  as  Chief
Executive  Officer,  as may  reasonably be assigned to Employee by the Company's
Board of Directors from time to time.

                                       1
<PAGE>

3.    Compensation

      As compensation,  PharmaFrontiers  shall pay Employee a salary of $250,000
per year, paid monthly. In addition,  PharmaFrontiers grants to Employee a three
year option to purchase up to 370,000 shares of common stock of  PharmaFrontiers
the  terms of  which  are set  forth in the  Incentive  Stock  Option  Agreement
attached  hereto as Exhibit "A" (the  "Option  Agreement").  Upon the signing of
this Agreement,  Employee agrees to sign and be bound to the terms of the Option
Agreement.

4.    Benefits

      PharmaFrontiers  will provide  Employee  with the  benefits and  insurance
coverage as generally provided by  PharmaFrontiers to its management  employees,
but only if and when such  benefits  and/or  coverage  are  provided.  As of the
Effective  Date, no such benefits or coverage are  provided.  If provided,  such
benefits and insurance coverages may be changed by PharmaFrontiers  from time to
time.

5.    Confidential and Proprietary Information; Documents

      5.1 PharmaFrontiers  shall provide Employee with information deemed secret
and confidential by PharmaFrontiers.  Such secret or confidential information or
know-how  of   PharmaFrontiers   (referred  to  collectively  as   "Confidential
Information") shall include,  without limitation,  the following: the status and
plans  for  research  and  development;  materials,  cells,  tissues,  and other
biological samples and specimens; cell banking methods, apparatus, and services;
pending and planned patent  applications (until published by the Patent Office);
invention disclosures;  research and technical data and information;  methods of
creating,  preparing,  and using  stem  cells and  other  biological  materials;
license,  sublicense,  and other  agreements  relating to intellectual  property
rights;  PharmaFrontiers'  plans;  customer or contact information;  contributor
information;  strategies,  costs,  prices,  uses,  applications  of products and
services; results of and data from investigations or experiments; all apparatus,
products, processes, compositions, samples, formulas, computer programs, pricing
policy,  financial  information,  and methods of doing  business;  policy and/or
procedure manuals,  training and recruiting  procedures;  accounting procedures;
the status and  content of  PharmaFrontiers'  contracts  with its  contributors,
clients,  and customers;  PharmaFrontiers'  business  philosophy,  and servicing
methods and  techniques;  all at any time used,  developed,  or  investigated by
PharmaFrontiers, before or during the Employee's tenure of employment, which are
not generally available to the public or which are maintained as confidential by
PharmaFrontiers.

      5.2 Employee recognizes and acknowledges that Employee will have access to
certain information of PharmaFrontiers  that is confidential and proprietary and
constitutes  valuable and unique  property of  PharmaFrontiers.  Employee agrees
that  Employee  will not at any time,  either during or subsequent to Employee's
employment,  disclose  to others,  use,  copy or permit to be copied,  except in
pursuance of Employee's  duties on behalf of  PharmaFrontiers,  its  successors,
assigns or nominees, any Confidential Information or know-how of PharmaFrontiers

                                       2
<PAGE>

(whether  or not  developed  by the  Employee)  without  PharmaFrontiers'  prior
written  consent.   Employee  further  agrees  to  maintain  in  confidence  any
confidential  information  of third  parties  received as a result of Employee's
employment with PharmaFrontiers.

      5.3  Employee  further  agrees  to  deliver  to   PharmaFrontiers  at  the
termination of Employee's  employment all biological  materials  correspondence,
memoranda,  notes, records,  drawings,  sketches, plans, customer, client and/or
contributor  lists,  product  compositions,  or other  documents  and all copies
thereof  (all of which are  hereafter  referred  to as the  "Documents"),  made,
composed or received by Employee,  solely or jointly with others,  and which are
in Employee's possession, custody, or control at such date and which are related
in any manner to the past, present, or anticipated  business of PharmaFrontiers.
In this regard, Employee hereby grants and conveys to PharmaFrontiers all right,
title  and  interest  in and to,  including  without  limitation,  the  right to
possess,  print,  copy,  and  sell  or  otherwise  dispose  of,  any  biological
materials,  reports, records, papers summaries,  photographs,  drawings or other
documents,  and writings,  copies,  abstracts or summaries thereof, or any other
works of  authorship,  which may be prepared  by  Employee  or under  Employee's
direction  or which may come into  Employee's  possession  in any way during the
term of Employee's employment with PharmaFrontiers which relate in any manner to
the past, present or anticipated business of PharmaFrontiers.

      5.4 Employee  further  agrees that  Employee will not,  during  Employee's
employment,   receive  from  persons  not  employed  by   PharmaFrontiers,   any
confidential  information  not  belonging  to  PharmaFrontiers,  unless  a valid
agreement is signed by both an officer of PharmaFrontiers  and by the disclosing
party  that  states  that   PharmaFrontiers   will  not  be  in  a  confidential
relationship  with the disclosing  party.  Employee further agrees that Employee
will  not  use  or  disclose  to  other  employees  of  PharmaFrontiers,  during
Employee's employment with PharmaFrontiers,  confidential  information belonging
to  Employee's  former  employers,  or any other third  parties  unless  written
permission  has been  given by such  persons  to  PharmaFrontiers  to use and/or
disclose such information.

      5.5 In the event of a breach or threatened breach of any of the provisions
of Section 5,  PharmaFrontiers  shall be entitled to an injunction  ordering the
return of such Documents and any and all copies thereof and restraining Employee
from using or disclosing,  for Employee's  benefit or the benefit of others,  in
whole or in part, any Confidential Information, including but not limited to the
Confidential  Information which such Documents contain,  constitute,  or embody.
Employee  further  agrees  that any  breach or  threatened  breach of any of the
provisions of Section 5 would cause irreparable  injury to  PharmaFrontiers  for
which it would have no adequate remedy at law. Nothing herein shall be construed
as prohibiting  PharmaFrontiers from pursuing any other remedies available to it
for any such breach or threatened breach, including the recovery of damages.

6.    Noncompetition/No-Hire Agreement

      6.1 Employee  agrees that,  from the Effective  Date until a period of one
year  following  the  date of the  termination  of  Employee's  employment  (the
"Noncompetition Period"), Employee will not directly or indirectly, either as an
employee, employer,  consultant,  agent, principal,  partner, corporate officer,

                                       3
<PAGE>

director,  or in any other  individual  or  representative  capacity,  engage or
participate  in any  "Competitive  Business"  anywhere  in the United  States of
America  (the  "Noncompetition  Territory").  As  used  herein,  a  "Competitive
Business"  is defined as any  business  relating to stem cells or cell  banking,
which the Company is currently  involved or will be involved  during the term of
this Agreement.

      6.2  Employee  further  agrees that during the  Noncompetition  Period and
within the  Noncompetition  Territory Employee will not, directly or indirectly,
either  as  an  employee,  employer,   consultant,  agent,  principal,  partner,
corporate  officer,  director,  or in any  other  individual  or  representative
capacity, call on, solicit, recruit, or attempt to call on, solicit, or recruit,
or  attempt  to hire any of the  employees  of  PharmaFrontiers,  regardless  of
whether  for the  benefit of the  Employee  or for any other  person,  firm,  or
corporation.

      6.3  Employee  shall not during the  Noncompetition  Period and within the
Noncompetition  Territory,  either  directly or indirectly (i) make known to any
Competitive  Business  the  names  and  addresses  of  any  of  PharmaFrontiers'
customers  or contacts or any other  information  pertaining  to such persons or
businesses  or (ii) call on,  solicit,  or take  away,  or  attempt  to call on,
solicit or take away any of the customers of PharmaFrontiers  with whom Employee
became acquainted during Employee's association with PharmaFrontiers, regardless
of whether for the  benefit of the  Employee  or for any other  person,  firm or
corporation.

      6.4  Employee  agrees  that the  restraints  created by the  covenants  in
Section 6 are no greater than necessary to protect  PharmaFrontiers'  legitimate
interests.  Furthermore, Employee agrees that such covenants of Section 6 do not
hinder,  or  otherwise  cause  hardship to  Employee  in finding and  performing
employment  elsewhere upon  termination of this Agreement.  Similarly,  Employee
agrees that  PharmaFrontiers'  need for the protection afforded by the covenants
of Section 6 is not  outweighed by either the hardship to Employee or any injury
likely to the public.

      6.5 Employee agrees that this Section is ancillary to this Agreement,  and
independent  of any  other  agreement  related  to  Employee's  employment  with
PharmaFrontiers,  and  Employee  acknowledges  that the  consideration  given by
PharmaFrontiers  for  this  Agreement  includes  PharmaFrontiers'  agreement  to
provide  to the  Employee  access to the  Confidential  Information,  as well as
employment.  Further,  the existence of any claim or cause of action of Employee
against   PharmaFrontiers   or   any   officer,   director,   or   employee   of
PharmaFrontiers,  whether  predicated on this Agreement or otherwise,  shall not
constitute  a  defense  to the  enforcement  by  PharmaFrontiers  of  Employee's
covenants  contained  in this  Agreement.  In  addition,  this  Agreement  shall
continue  to  be  binding   upon   Employee  in   accordance   with  its  terms,
notwithstanding the termination of Employee's employment.

      6.6  Employee  agrees  that  Employee's  breach  or  violation,  or threat
thereof,  of this covenant not to compete shall  entitle  PharmaFrontiers,  as a
matter of right, to an injunction  without the necessity of posting bond, issued
by any court of  competent  jurisdiction,  restraining  any further or continued
breach or  violation  of this  covenant.  Such right to an  injunction  shall be
cumulative  and in addition to, and not in lieu of, any other  remedies to which

                                       4
<PAGE>

PharmaFrontiers may show itself justly entitled.  Further,  during any period in
which Employee is in breach of this covenant not to compete,  the time period of
this  covenant  shall be  extended  for an amount of time  that  Employee  is in
breach.

7.    Inventions and Other Intellectual Property

      7.1  Employee  agrees  to hold  in  complete  trust  for  the  benefit  of
PharmaFrontiers,  and to  disclose  promptly  and  fully to  PharmaFrontiers  in
writing,   and  hereby  assigns,   and  binds   Employee's   heirs,   executors,
administrators,  and all legal representatives to assign, to PharmaFrontiers any
and all inventions,  discoveries, ideas, concepts,  improvements,  copyrightable
works,  biological  materials,  and  other  developments  (all of the  above are
collectively referred to as the "Developments")  conceived,  made, discovered or
developed by him, solely or jointly with others, during Employee's employment by
PharmaFrontiers, whether during or outside of usual working hours and whether on
PharmaFrontiers'  premises  or not,  which  relate  in any  manner  to the past,
present  or  anticipated   business  of   PharmaFrontiers.   Any  and  all  such
Developments  shall be the  sole  and  exclusive  property  of  PharmaFrontiers,
whether patentable, copyrightable, or neither, and Employee agrees that Employee
will assist and fully cooperate in every way, at  PharmaFrontiers'  expense,  in
securing,  maintaining, and enforcing, for the benefit of PharmaFrontiers or its
designee,  patents,  copyrights or other types of  proprietary  or  intellectual
property  protection for such  Developments  in any and all countries.  Employee
acknowledges and agrees that any and all such Developments  conceived,  created,
or authored by him within the scope of Employee's employment is a "work made for
hire," as defined by the federal copyright laws, and therefore all copyrights in
and to such works are and will be owned by  PharmaFrontiers.  To the extent that
Employee  authors any  copyrightable  work in any medium during the Term of this
Agreement which relates or pertains in any way to  PharmaFrontiers or any of the
operations or  activities of either and which was not prepared  within the scope
of  Employee's  employment,  Employee  hereby  assigns  all  right,  title,  and
interest,  including but not limited to all rights of copyright,  in and to such
works to  PharmaFrontiers.  Within  six  months  following  the  termination  of
Employee's employment, and without limiting the generality of the foregoing, any
Development of the Employee  relating to any  PharmaFrontiers  subject matter on
which  Employee  worked  or  was  informed  during   Employee's   employment  by
PharmaFrontiers  shall be conclusively  presumed to have been conceived and made
prior to the termination of Employee's  employment  (unless the Employee clearly
proves that such Development was conceived and made following the termination of
Employee's  employment),  and shall  accordingly  belong,  and be  assigned,  to
PharmaFrontiers and shall be subject to this Agreement.

      7.2 Without  limiting  the  foregoing,  Employee  agrees at the request of
PharmaFrontiers (but without additional compensation from PharmaFrontiers during
Employee's  employment  by  PharmaFrontiers)  to execute  any and all papers and
perform  all  lawful  acts  which   PharmaFrontiers   deems  necessary  for  the
preparation,  filing,  prosecution,  and maintenance of applications  for United
States and foreign letters patent, or for United States and foreign  copyrights,
on the  Developments,  and to  execute  such  instruments  as are  necessary  or
convenient to assign to  PharmaFrontiers,  its successors,  assigns or nominees,

                                       5
<PAGE>

all of the Employee's  right,  title,  and interest in the  Developments and the
like,  so  as  to  establish,  maintain  or  perfect,  in  PharmaFrontiers,  its
successors,  assigns or nominees,  the entire right,  title, and interest to the
Developments,   and  also  to  execute  any   instruments   necessary  or  which
PharmaFrontiers may deem desirable it connection with any continuation,  renewal
or reissue thereof, or in the conduct of any proceedings or litigation in regard
thereto.

      7.3 All expenses  incurred by the Employee by reason of the performance of
any of the obligations set forth in this Section on Inventions shall be borne by
PharmaFrontiers.    Should   the   Employee's   assistance   be   requested   by
PharmaFrontiers   after   termination  of  employment,   PharmaFrontiers   would
compensate the Employee at a reasonable rate.

8.    Conflicts of Interest

      8.1 In  keeping  with  Employee's  fiduciary  duties  to  PharmaFrontiers,
Employee agrees that Employee shall not, directly or indirectly, become involved
in any conflict of interest with  reference to any  transaction  or  opportunity
including PharmaFrontiers  ("Conflict"), or upon discovery thereof, allow such a
Conflict to continue.  Moreover,  Employee  agrees that Employee  shall promptly
disclose  to the Board of  PharmaFrontiers  any facts  which  might  involve any
reasonable  possibility  of a  Conflict.  Employee  shall  maintain  the highest
standards of conduct,  and shall not do anything likely to injure the reputation
or goodwill of  PharmaFrontiers,  or  embarrass or  otherwise  generate  adverse
publicity for or bring unwanted attention to PharmaFrontiers.

      8.2 It is agreed that any direct or indirect interest in, connection with,
or benefit  from any outside  activities,  particularly  commercial  activities,
which interest might in any way adversely affect  PharmaFrontiers  or any of its
subsidiaries or affiliates, involves a possible Conflict. Circumstances in which
a Conflict on the part of Employee  would or might  arise,  and which  should be
reported  immediately  by  Employee to an officer of  PharmaFrontiers,  include,
without  limitation,  the  following:  (a) ownership of a material  interest in,
acting in any capacity for, or accepting  directly or  indirectly  any payments,
services or loans from a supplier, contractor,  subcontractor, customer or other
entity with which  PharmaFrontiers  does business;  (b) misuse of information or
facilities to which Employee has access in a manner which will be detrimental to
PharmaFrontiers'  interest; (c) disclosure or other misuse of information of any
kind  obtained  through the  Employee's  connection  with  PharmaFrontiers;  (d)
acquiring or trading in, directly or indirectly,  other  properties or interests
connected  with the design,  manufacture  or  marketing  of  products  designed,
manufactured  or  marketed  by  PharmaFrontiers;  (e) the  appropriation  to the
Employee or the diversion to others, directly or indirectly,  of any opportunity
in which it is known or could  reasonably be  anticipated  that  PharmaFrontiers
would  be  interested;  and (f) the  ownership,  directly  or  indirectly,  of a
material  interest in an enterprise in competition with  PharmaFrontiers  or its
dealers and distributors or acting as a director, officer, partner,  consultant,
employee or agent of any enterprise which is in competition with PharmaFrontiers
or its dealers or distributors.

                                       6
<PAGE>

9.    Activities   Associated  With  Maintenance  of  Professional   Status  and
      Community Activities

      PharmaFrontiers  will  reimburse  Employee  for the  costs  of  activities
associated with the maintenance of the Employee's professional status, including
the payment of licensing fees and required  continuing  education,  expenses for
professional/network meetings, as well as community activities.

10.   Prior Discoveries

      Employee  attaches hereto as Exhibit "B,"  concurrently with the execution
of this Agreement, a list and brief description of all unpatented inventions and
discoveries,  if any exist,  made or conceived by Employee  prior to  Employee's
employment  with  PharmaFrontiers  and  which  are  to  be  excluded  from  this
Agreement.  If no such  list  is  attached  at the  time  of  execution  of this
Agreement,  it shall be conclusively presumed that Employee has waived any right
Employee  may  have  to  any  such  invention  or  discovery  which  relates  to
PharmaFrontiers' business.

11.   Publicity

      11.1  Employee  agrees that  PharmaFrontiers  may use,  and hereby  grants
PharmaFrontiers  the nonexclusive  and worldwide right to use,  Employee's name,
picture, likeness,  photograph,  signature, or any other attribute of Employee's
persona  (all of such  attributes  are  hereafter  collectively  referred  to as
"Persona") in any media for any  advertising,  publicity or other purpose at any
time, either during or subsequent to Employee's  employment by  PharmaFrontiers.
Employee  agrees  that such use of  Employee's  Persona  will not  result in any
invasion or violation of any privacy or property  rights  Employee may have; and
Employee  agrees that Employee will receive no additional  compensation  for the
use of Employee's Persona. Employee further agrees that any negatives, prints or
other material for printing or reproduction purposes prepared in connection with
the use of  Employee's  Persona  by  PharmaFrontiers  shall  be and are the sole
property of PharmaFrontiers.

      11.2 Employee further agrees that at no time shall Employee write, author,
publish,  distribute,  or cause to be published or  distributed  any  pictorial,
graphic,  or literary works, such as but without  limitation,  books,  articles,
stories, or pamphlets, in any medium of expression, tangible or intangible, that
relate, describe, or pertain in any way to PharmaFrontiers or to the operations,
activities,  or employees of  PharmaFrontiers  without first obtaining the prior
written consent of the Board of Directors of  PharmaFrontiers  to do so and also
the prior  written  approval  of the  contents  of any such work by the Board of
Directors of PharmaFrontiers.

12.   Remedies

      Employee and  PharmaFrontiers  agree that,  because damages at law for any
breach or nonperformance of this Agreement by Employee,  while recoverable,  are
and will be  inadequate,  this  Agreement  may be enforced in equity by specific
performance, injunction, accounting or otherwise.

                                       7
<PAGE>

13.   Miscellaneous

      13.1 This  Agreement is made and entered into as of the Effective Date and
the rights and obligations of the parties hereto shall be binding upon the heirs
and legal  representatives  of the  Employee and the  successors  and assigns of
PharmaFrontiers.  This  Agreement  may be  assigned  by  PharmaFrontiers  but is
personal to the  Employee and no rights,  duties,  and  obligations  of Employee
hereunder may be assigned.

      13.2 No waiver or non-action with respect to any breach by the other party
of any provision of this Agreement, nor the waiver or non-action with respect to
any breach of the provisions of similar agreements with other employees shall be
construed to be a waiver of any  succeeding  breach of such  provision,  or as a
waiver of the provision itself.

      13.3  Should  any  portions  hereof  be held to be  invalid  or  wholly or
partially unenforceable, such holding shall not invalidate or void the remainder
of this  Agreement.  The portions held to be invalid or  unenforceable  shall be
revised and reduced in scope so as to be valid and  enforceable,  or, if such is
not possible,  then such portions  shall be deemed to have been wholly  excluded
with the same force and effect as if it had never been included herein.

      13.4 Employee's  obligations under this Agreement to PharmaFrontiers shall
survive the  termination,  for whatever  reason,  of  Employee's  employment  by
PharmaFrontiers.

      13.5 This Agreement supersedes,  replaces and merges any and all prior and
contemporaneous  understandings,  representations,  agreements  and  discussions
relating to the same or similar subject matter as that of this Agreement between
Employee  and  PharmaFrontiers  and  constitutes  the sole and entire  agreement
between the Employee and  PharmaFrontiers  with respect to the subject matter of
this Agreement.

      13.6 The laws of the State of Texas,  excluding  any conflicts of law rule
or  principle  that  might  otherwise  refer to the  substantive  law of another
jurisdiction,  will  govern  the  interpretation,  validity  and  effect of this
Agreement  without regard to the place of execution or the place for performance
thereof,  and  PharmaFrontiers  and  Employee  agree that the state and  federal
courts in Harris County,  Texas, shall have personal jurisdiction and venue over
PharmaFrontiers  and Employee to hear all disputes arising under this Agreement.
This Agreement is to be at least partially performed in Harris County, Texas.

      13.7 All notices and other communications  required or permitted hereunder
or necessary or convenient in connection  herewith shall be in writing and shall
be deemed to have been given when mailed by registered  mail or certified  mail,
return receipt requested, as follows:

      If to PharmaFrontiers, to:

      Mr. Warren C. Lau
      PharmaFrontiers Corporation
      18205 Burkhardt Road
      Tomball, TX 77377

      If to Employee, to:

      Mr. David B. McWilliams
      19 Misty Grove Circle
      The Woodlands, TX 77380

                                       8
<PAGE>

or to such other  addresses as either party may designate by notice to the other
party hereto in the manner specified in this section.

      13.8 This  Agreement  may not be  changed  or  terminated  orally,  and no
change,  termination  or waiver of this  Agreement  or of any of the  provisions
herein  contained  shall be binding  unless  made in writing  and signed by both
parties,  and in the  case  of  PharmaFrontiers,  by an  authorized  officer  of
PharmaFrontiers.  Any change or changes, from time to time, in Employee's salary
and/or duties shall not be, nor be deemed to be, a change, termination or waiver
of this Agreement or of any of the provisions herein contained.

PHARMAFRONTIERS CORPORATION                EMPLOYEE

By:  /s/ Warren Lau                        By:  /s/ David B. McWilliams
     --------------------------                 -----------------------------
     Warren C. Lau, President                   David B. McWilliams

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]